SCHEMBL23168932

SCHEMBL23168932

COc1ccc(Cn2cc(Oc3c(Cl)cc(-n4c(C)ccc4C)cc3Cl)ccc2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NPBWR1 P48145 12/20 0.43
▸ MCHR1 Q99705 2/20 0.42
▸ MAPT P10636 4/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TP53 P04637 2/20 0.40
▸ LMNA P02545 1/20 0.39
▸ SDHB P21912 1/20 0.39
▸ CMA1 P23946 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23168772 0.92 MAPT (0.43) NPBWR1MCHR1MAPTKDM4EALDH1A1
SCHEMBL23168653 0.91 MAPT (0.47) NPBWR1MCHR1MAPTTP53LMNA
SCHEMBL29821821 0.91 MAPT (0.47) NPBWR1MCHR1MAPTTP53LMNA
SCHEMBL23168941 0.90 THRB (0.38) NPBWR1MAPTKDM4EALDH1A1TP53
SCHEMBL29822173 0.87 P2RX7 (0.40) MAPTKDM4EALDH1A1LMNA
SCHEMBL23168950 0.87 P2RX7 (0.40) MAPTKDM4EALDH1A1LMNA
SCHEMBL24819258 0.87 NPBWR1 (0.39) NPBWR1MCHR1ALDH1A1SDHB
SCHEMBL23168748 0.84 P2RX7 (0.37) NPBWR1MAPTKDM4EALDH1A1LMNA
SCHEMBL23168931 0.84 NPBWR1 (0.46) NPBWR1MCHR1MAPTTP53LMNA
SCHEMBL23168636 0.83 PGR (0.37) NPBWR1MCHR1MAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2026-05-05 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-12-29 — — US disclosed
EP-4036090-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2022-08-03 — — EP disclosed
WO-2021057791-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF 广东东阳光药业有限公司 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411400-A1 CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF THRB, TSHR, THRA NPBWR1 336/4885MCHR1 251/4885MAPT 1873/4885
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof THRB, TSHR, THRA NPBWR1 267/4885MCHR1 223/4885MAPT 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback